(Q30978355)

27 June 2017

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data (English)

1 reference

27 June 2017

0 references

Johnson KP

1

1 reference

27 June 2017

Ford CC

series ordinal

2

1 reference

27 June 2017

Lisak RP

series ordinal

3

1 reference

27 June 2017

Wolinsky JS

series ordinal

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Acta Neurologica Scandinavica

27 June 2017

1 reference

27 June 2017

111

1 reference

27 June 2017

1

1 reference

27 June 2017

42-47

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

27 June 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2004.00351.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2004.00351.X

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2004.00351.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2004.00351.X

10.1111/J.1600-0404.2004.00351.X

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference